secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROCRINE BIOSCIENCES INC (NBIX)
CIK:        0000914475
Form:       8-K
Filed at:   2026-09-28T20:20:24+00:00
Accession:  0000914475-26-000045
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02
LLM model:  deepseek-v4.1-flash:cloud@v2

Neurocrine names Eiry W. Roberts Chief Medical Officer; Sanjay Keswani exits under mutual agreement
--------------------------------------------------------------------------------

- Eiry W. Roberts, M.D. appointed Chief Medical Officer effective September 28, 2026, succeeding Sanjay Keswani, M.D.
- Keswani and the Board mutually agreed his CMO service terminated September 25, 2026; he receives severance under Section 4.1 of the Executive Severance Plan.
- Roberts will earn a base salary of $825,000 and a target annual cash bonus equal to 60% of 2026 base pay earned.
- Equity grants: options target ~$625,000 vesting monthly over four years; RSUs ~$250,000 and performance RSUs ~$375,000 vesting annually over four years.
- Grants auto-issue two business days after the first 10-Q following the transition date; Employment Agreement to be filed with the Q3 2026 10-Q.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/914475/000091447526000045/0000914475-26-000045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/914475/000091447526000045/nbix-20260925.htm
  HTML page:      https://secwatch.observer/filing/0000914475-26-000045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer